Efficacy and safety of sequencing with vemurafenib (V) plus cobimetinib (C) followed by atezolizumab (Atezo) in patients (pts) with advanced BRAF(V600)-positive melanoma: Interim analysis of the ImmunoCobiVem study.

Results

Title:	Efficacy and safety of sequencing with vemurafenib (V) plus cobimetinib (C) followed by atezolizumab (Atezo) in patients (pts) with advanced BRAF(V600)-positive melanoma: Interim analysis of the ImmunoCobiVem study.
Authors :	Schadendorf, Dirk; ...; Kandolf-Sekulovic, Lidija O; ...; Mijuskovic, Željko P ; ...; (broj, koautora 20)
Issue Date:	2022
Publication:	JOURNAL OF CLINICAL ONCOLOGY
ISSN:	0732-183X e1527-7755 Journal of Clinical Oncology Search Idenfier
Publisher:	American Society of Clinical Oncology
Type:	Conference Paper
Collation:	vol. 40 br. 16_suppl str. 9548-9548
DOI:	10.1200/jco.2022.40.16_suppl.9548
WoS-ID:	000863680302367
URI:	https://enauka.gov.rs/handle/123456789/810661
URL:	https://ascopubs.org/doi/pdfdirect/10.1200/JCO.2022.40.16_suppl.9548
Project:	F. Hoffmann-La Roche Ltd.
Metadata source:	(Preuzeto iz Nasi u WoS)
M-category:	Mp. category will be shown later

Altmetric

Dimensions

Unpaywall

Google Scholar^TM